image credit- shutterstock
Lotus Pharmaceutical, a global pharmaceutical company headquartered in Taiwan, has entered into an agreement with OM Pharma, a global biopharmaceutical company headquartered in Geneva, Switzerland to acquire the assets of a specialty biopharmaceutical product for the prevention of recurrent urinary tract infections in South Korea including the transfer of marketing authorisations, trademarks, finished product inventory, and other relevant intellectual property rights.
The acquisition is expected to strengthen Lotus’ specialty portfolio and further expand its presence in South Korea, one of the company’s key Asian markets.
The acquired product has an established clinical profile and long-standing market presence, with a differentiated positioning within its therapeutic category. It is currently marketed in more than 40 countries and reached approximately over one million patients globally in 2025. South Korea represents a key market, supported by strong physician endorsement and clinical engagement.
Petar Vazharov, Chief Executive Officer of Lotus, commented, “This acquisition in South Korea advances a deliberate strategy to further strengthen Lotus’ position in the market. It reflects our conviction to build a portfolio of differentiated brands that duly address patients’ needs."
